MilliporeSigma Opens New €290 Million Biosafety Testing Facility in Rockville, Maryland, USA

• Facility consolidates biosafety testing, analytical development, and cell bank manufacturing services into single building
• New rapid test offering with Blazar^® CHO Animal Origin Free (AOF) delivers results 60% faster
• Enables the company to meet increased global demand for biosafety testing

BURLINGTON, Mass.--(BUSINESS WIRE)--MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has opened its new €290 million biosafety testing facility in Rockville, Maryland, USA. Biosafety testing and analytical development are fundamental components of drug development and commercialization for traditional and novel modalities. Global demand for these services is growing at a double-digit rate¹.

“It reflects our commitment to providing our clients with disruptive platforms that shorten biosafety testing timelines, meet the growing global demand, and ensure the safety of the world’s medicines for patients.”

“This expansion is the largest investment in contract testing in the company’s history and will allow us to drive automation and technology development in one integrated hub,” said Benjamin Hein, Head of Life Science Services, Life Science business of Merck KGaA, Darmstadt, Germany. “It reflects our commitment to providing our clients with disruptive platforms that shorten biosafety testing timelines, meet the growing global demand, and ensure the safety of the world’s medicines for patients.”

The 23,000-square-meter facility will house biosafety testing, analytical development, and cell banking manufacturing services. It consolidates labs currently spread across four buildings into a single facility. This will increase collaboration between scientists and enable a higher level of automation and digitalization to increase Right First Time (RFT).

The Life Science business of Merck KGaA, Darmstadt, Germany, has made significant investments over the last five years to expand its biosafety testing capabilities for clients across the globe. The company’s global biosafety testing network includes sites in Shanghai, China; Singapore; Stirling and Glasgow, UK; and Rockville, MD, USA.

The new site will feature advanced testing capabilities, including a rapid methods package, designed to accelerate virus testing of bulk harvest material. This package is the first to include the Blazar^® CHO Animal Origin Free (AOF) panel, a targeted molecular method for detecting virus families. By combining the Blazar^® CHO AOF panel with assays for mycoplasma, sterility, and retrovirus-like particle detection, test results can be obtained in just 14 days, compared to 35 days with traditional assay methods.

The Life Science business of Merck KGaA, Darmstadt, Germany, offers a broad multi-modality testing portfolio, which features disruptive platforms that reduce biosafety testing timelines and deliver the highest quality standards. The portfolio includes a rapid methods package with the Blazar^® CHO AOF panel, and the recently launched Aptegra™ platform, the first all-in-one, validated genetic stability assay of its kind. These innovations will enable the company to continue delivering high-quality testing services and regulatory expertise to bring life-changing medicines to patients more quickly and safely.

About the Life Science business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 27,000 employees and more than 55 total manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.

Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck KGaA, Darmstadt, Germany, generated sales of € 21 billion in 65 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit http://www.emdgroup.com

Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.
All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

^{_________________________
1} https://www.gminsights.com/industry-analysis/biological-safety-testing-market

Media Relations
Rachel Bloom-Baglin
rachel.bloom-baglin@milliporesigma.com
Phone: +1 978 436 1725